M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV Research

Executive Summary: M344 is a highly potent, cell-permeable histone deacetylase inhibitor (HDACi) with an IC50 of 100 nM, validated in multiple cancer cell lines and HIV-1 latency models (APExBIO product page). It induces histone acetylation and modulates gene expression, leading to robust apoptosis and differentiation responses. M344 enhances radiosensitivity, is active in both p53-dependent and -independent pathways, and is soluble in DMSO/ethanol but not water. The compound is supplied by APExBIO for research use only, with established protocols for dosing and storage (Klotz 2009).

Biological Rationale

Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone tails, condensing chromatin structure and repressing gene expression. Aberrant HDAC activity contributes to oncogenesis, resistance to apoptosis, and maintenance of viral latency. Pharmacological HDAC inhibition results in increased histone acetylation and reactivation of silenced genes, providing a rationale for targeting HDACs in oncology and virology (related article). M344 was developed to address limitations in cell permeability and potency observed with early-generation HDAC inhibitors.

Mechanism of Action of M344

M344 inhibits HDAC enzymatic activity with an IC50 of 100 nM in vitro. This inhibition leads to global increases in histone acetylation, chromatin relaxation, and transcriptional reactivation of genes involved in cell cycle arrest and apoptosis. M344 is cell-permeable, enabling effective intracellular HDAC inhibition. It induces pro-apoptotic factors such as Puma via p53-independent pathways and regulates NF-κB transcriptional activity. In HIV-1 latency models, M344 activates the HIV-1 LTR, facilitating latency reversal (see also: robust cell-based evidence).

Evidence & Benchmarks

• M344 demonstrates an HDAC inhibition IC50 of 100 nM under cell-free biochemical assay conditions (37°C, pH 7.4) (APExBIO).
• In MCF-7 breast cancer cells, the GI50 for proliferation inhibition is 0.63 μM (72 h, standard media) (Klotz 2009).
• Medulloblastoma (D341 MED) and neuroblastoma (CH-LA 90) cell lines exhibit GI50 values of 0.65 μM (72 h) (M344: Potent HDAC Inhibitor).
• M344 enhances radiosensitivity in human squamous carcinoma lines SCC-35 and SQ-20B (combined treatment, 24–48 h) (M344: Reliable HDAC Inhibition).
• M344 upregulates Puma and modulates NF-κB in p53-null models (apoptosis induction, 24–48 h) (Advancing HDAC Inhibition).
• The compound induces HIV-1 LTR gene expression in latency models, supporting anti-latency therapy research (1–10 μM, 24 h) (APExBIO).

Applications, Limits & Misconceptions

M344 is widely used in:

• Apoptosis assays and cell viability/proliferation inhibition in oncology research.
• Induction of cell differentiation and epigenetic modulation in solid and hematological tumor models.
• HIV-1 latency reversal protocols as a latency-reversing agent (LRA).
• Combination therapy studies to potentiate radiation or standard chemotherapeutics.

Compared to prior reviews such as Next-Generation HDAC Inhibition, this article provides updated benchmarks and protocol optimization details for translational workflows.

Common Pitfalls or Misconceptions

• M344 is insoluble in water; improper solubilization can yield irreproducible results (APExBIO).
• It is not recommended for diagnostic or clinical use; it is strictly for preclinical research.
• Long-term storage in solution is discouraged due to compound degradation; stock solutions should be stored at -20°C and used promptly.
• Activity and cytotoxicity are highly cell-type dependent; not all cancer lines respond equally.
• M344’s effects on non-HDAC targets are minimal but possible at high concentrations (>100 μM).

Workflow Integration & Parameters

M344 (SKU A4105) is supplied as a solid and should be handled under low temperatures with blue ice shipping. Stock solutions are prepared in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL, ultrasonic treatment recommended). Typical working concentrations are 1–100 μM, with treatment durations ranging from 1 to 7 days depending on assay design. Controls should include vehicle-only and HDAC-insensitive cell lines where possible. For consistent results, researchers are advised to reference APExBIO’s validated protocols (APExBIO).

Conclusion & Outlook

M344 is an established, potent HDAC inhibitor that enables precise interrogation of HDAC signaling pathways in cancer and HIV-1 latency research. Its robust cell permeability, low nanomolar potency, and reproducible performance across multiple platforms set it apart from earlier-generation HDACis. For future workflows, M344 is well positioned to support combinatorial and translational studies in precision oncology and virology. For procurement, refer to the M344 product page from APExBIO.